A share price of Lexicon Pharmaceuticals Inc [LXRX] is currently trading at $1.65, up 7.14%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXRX shares have gain 3.12% over the last week, with a monthly amount drifted -25.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on April 30, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $5. Previously, Jefferies started tracking the stock with Hold rating on March 07, 2023, and set its price target to $3. On August 12, 2022, Piper Sandler initiated with a Overweight rating and assigned a price target of $10 on the stock. JP Morgan upgraded its rating to a Neutral but stick to its price target of $7 on January 29, 2021. Wedbush downgraded its rating to a Neutral and raised its price target to $8 on January 29, 2021. Citigroup upgraded its rating to Buy for this stock on December 08, 2020. In a note dated November 18, 2020, Gabelli & Co upgraded an Buy rating on this stock.
Lexicon Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.92 and $3.79. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $1.65 at the most recent close of the market.
Analyzing the LXRX fundamentals
Trailing Twelve Months sales for Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] were 1.21M which represents 2407.14% growth. Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at -142.53%, Pretax Profit Margin comes in at -145.73%, and Net Profit Margin reading is -144.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.14 and Total Capital is -0.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5167 points at the first support level, and at 1.3833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7767, and for the 2nd resistance point, it is at 1.9033.
Lexicon Pharmaceuticals Inc [LXRX] reported earnings per share of -$0.2 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.22/share, meaning a difference of $0.02 and a surprise factor of 9.10%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.21 per share as compared to estimates of -$0.21 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] is 5.60. Also, the Quick Ratio is 5.58, while the Cash Ratio stands at 0.71. Considering the valuation of this stock, the price to sales ratio is 335.78, the price to book ratio is 4.34.
Transactions by insiders
Recent insider trading involved COATS LONNEL, Chief Executive Officer, that happened on Nov 16 ’23 when 90000.0 shares were purchased. Chief Executive Officer, COATS LONNEL completed a deal on Nov 10 ’23 to buy 10000.0 shares. Meanwhile, Director DEBBANE RAYMOND bought 0.15 million shares on Oct 12 ’23.
